Skip to main content
Top
Published in:

Open Access 08-10-2024 | Obstructive Sleep Apnea | REVIEW

Estimating Cardiovascular Benefits of Tirzepatide in Sleep Apnea and Obesity: Insight from the SURMOUNT-OSA Trials

Authors: Guglielmo Beccuti, Fabio Bioletto, Mirko Parasiliti-Caprino, Andrea Benso, Ezio Ghigo, Alessandro Cicolin, Fabio Broglio

Published in: Current Obesity Reports | Issue 4/2024

Login to get access

Abstract

Purpose of Commentary

This commentary aims to offer a perspective on the effect of tirzepatide on hypoxic burden and provide indirect evidence of cardiovascular risk reduction after tirzepatide for the treatment of obstructive sleep apnea and obesity. It also discusses the role of tirzepatide-induced weight loss in the management of obstructive sleep apnea.
Recent Findings.
In the SURMOUNT-OSA phase 3 trials, tirzepatide, a new GIP/GLP-1 receptor co-agonist, reduced the apnea–hypopnea index, hypoxic burden, and body weight in adults with moderate-to-severe obstructive sleep apnea and obesity. The change in apnea–hypopnea index is clinically relevant, but its impact on cardiovascular mortality remains unclear. Conversely, hypoxic burden predicts cardiovascular mortality across populations independent of AHI.

Summary

We attempted to postulate the magnitude of cardiovascular benefits of tirzepatide based on the reduction in hypoxic burden. Tirzepatide treatment for obstructive sleep apnea and obesity seems to result in hypoxic burden values associated with a lower cardiovascular mortality rate and thus might attenuate the negative cardiovascular impact of hypoxic burden.
Literature
11.
Metadata
Title
Estimating Cardiovascular Benefits of Tirzepatide in Sleep Apnea and Obesity: Insight from the SURMOUNT-OSA Trials
Authors
Guglielmo Beccuti
Fabio Bioletto
Mirko Parasiliti-Caprino
Andrea Benso
Ezio Ghigo
Alessandro Cicolin
Fabio Broglio
Publication date
08-10-2024
Publisher
Springer US
Published in
Current Obesity Reports / Issue 4/2024
Electronic ISSN: 2162-4968
DOI
https://doi.org/10.1007/s13679-024-00592-x

Other articles of this Issue 4/2024

Current Obesity Reports 4/2024 Go to the issue

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more